Literature DB >> 7724473

Applying Bailer's method for AUC confidence intervals to sparse sampling.

J R Nedelman1, E Gibiansky, D T Lau.   

Abstract

Bailer developed a method for constructing confidence intervals for areas under the concentration-vs-time curve (AUC's) with only one sample per subject but with multiple subjects sampled at each of several time points post dose. We have modified this method to account for estimation of the variances. How the need to estimate variances affects study design is discussed. An extension of Bailer's method is proposed where variances are modeled as a function of the means, in order to get more precise estimates of variances. The modified and extended methods are applied to a rat toxicokinetic study with only two rats per time point per treatment group.

Entities:  

Mesh:

Year:  1995        PMID: 7724473     DOI: 10.1023/a:1016255124336

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  4 in total

1.  An approximate distribution of estimates of variance components.

Authors:  F E SATTERTHWAITE
Journal:  Biometrics       Date:  1946-12       Impact factor: 2.571

2.  Testing for the equality of area under the curves when using destructive measurement techniques.

Authors:  A J Bailer
Journal:  J Pharmacokinet Biopharm       Date:  1988-06

3.  Assessing drug exposure in rodent toxicity studies without satellite animals.

Authors:  J R Nedelman; E Gibiansky; F L Tse; C Babiuk
Journal:  J Pharmacokinet Biopharm       Date:  1993-06

4.  Estimation of variance for AUC in animal studies.

Authors:  J Yuan
Journal:  J Pharm Sci       Date:  1993-07       Impact factor: 3.534

  4 in total
  44 in total

1.  Type 7 adenylyl cyclase-mediated hypothalamic-pituitary-adrenal axis responsiveness: influence of ethanol and sex.

Authors:  Sergey P Pronko; Laura M Saba; Paula L Hoffman; Boris Tabakoff
Journal:  J Pharmacol Exp Ther       Date:  2010-04-02       Impact factor: 4.030

2.  Estimation of AUC from 0 to Infinity in Serial Sacrifice Designs.

Authors:  Martin Josef Wolfsegger; Thomas Jaki
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-12       Impact factor: 2.745

3.  Establishing bioequivalence in serial sacrifice designs.

Authors:  Martin J Wolfsegger
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-10-12       Impact factor: 2.745

4.  Non-compartmental estimation of pharmacokinetic parameters in serial sampling designs.

Authors:  Martin J Wolfsegger; Thomas Jaki
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-10-22       Impact factor: 2.745

5.  Estimation of confidence intervals for area under the curve from destructively obtained pharmacokinetic data.

Authors:  R C Gagnon; J J Peterson
Journal:  J Pharmacokinet Biopharm       Date:  1998-02

6.  Sparse sampling for assessment of drug exposure in toxicological studies.

Authors:  P Burtin; F Mentre; J van Bree; J L Steimer
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1996 Apr-Jun       Impact factor: 2.441

7.  Coverage and precision of confidence intervals for area under the curve using parametric and non-parametric methods in a toxicokinetic experimental design.

Authors:  P L Bonate
Journal:  Pharm Res       Date:  1998-03       Impact factor: 4.200

8.  Design and inference for 3-stage bioequivalence testing with serial sampling data.

Authors:  Fangrong Yan; Huihong Zhu; Junlin Liu; Liyun Jiang; Xuelin Huang
Journal:  Pharm Stat       Date:  2018-05-03       Impact factor: 1.894

9.  Bayesian approach to estimate AUC, partition coefficient and drug targeting index for studies with serial sacrifice design.

Authors:  Tianli Wang; Kyle Baron; Wei Zhong; Richard Brundage; William Elmquist
Journal:  Pharm Res       Date:  2013-10-03       Impact factor: 4.200

10.  Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases.

Authors:  Rajendar K Mittapalli; Shruthi Vaidhyanathan; Arkadiusz Z Dudek; William F Elmquist
Journal:  J Pharmacol Exp Ther       Date:  2012-12-17       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.